Every now and then, scientists develop treatments that end up being even more popular for another condition entirely. Think of Viagra, originally for high blood pressure, now used for erectile dysfunction. Or thalidomide, ...
Apr 2, 2024
0
0
Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.
Mar 8, 2024
0
10
The biggest quandary in the obesity drug market is that nobody knows just how big it will be. Everyone agrees it'll be huge—currently, Eli Lilly & Co. is worth more than Tesla Inc., and Novo Nordisk A/S is at times the ...
Feb 12, 2024
0
1
Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound.
Jan 5, 2024
0
1
Managing diabetes will be a less expensive proposition for more Americans in 2024.
Jan 2, 2024
0
9
Wegovy, Mounjaro, Ozempic... These new drugs drawing such intense attention have raised the hopes of millions around the world suffering from diabetes or obesity. But what are they, how are they used and who makes them?
Dec 4, 2023
0
0
Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.
Dec 4, 2023
0
0
Obesity rates in the U.S. have been rising steadily for well over a decade and some of the world's biggest drug developers are tapping into the growing treatment market.
Nov 16, 2023
0
0
The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful—and lucrative—new obesity medicines.
Nov 8, 2023
0
0
Another diabetes drug maker is taking legal action against businesses in several states, alleging that they're "fraudulently claiming" that their compounded products are the same as its medication.
Sep 21, 2023
0
1
